Statistically significant lower risk is seen for mortality, hospitalization, progression, recovery, cases, and viral clearance. 20 studies from 14 independent teams in 4 countries show statistically significant improvements.
Meta analysis using the most serious outcome reported shows 52% [34‑65%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.
Results are robust — in exclusion sensitivity analysis 13 of 27 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
Efficacy is variant dependent. In Vitro studies suggest a lack of efficacy for many omicron variants Haars, Liu, Pochtovyi, Sheward, Tatham, VanBlargan. ADE shown In Vitro Shimizu. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Choudhary, Günther, Leducq.
Prescription treatments have been preferentially used by patients at lower risk Wilcock. Retrospective studies may overestimate efficacy, for example patients with greater knowledge of effective treatments may be more likely to access prescription treatments but result in confounding because they are also more likely to use known beneficial non-prescription treatments.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix. Wicaksono present another meta analysis for casirivimab/imdevimab, showing significant improvements for mortality, hospital discharge, progression, and viral clearance.
Covid Analysis et al., Mar 2024, preprint, 1 author.